ClinicalTrials.gg
CompletedNCT00022672Updated Jun 13, 2013Results posted

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

A Phase 3 interventional study of trastuzumab (Herceptin®) and anastrazole (Arimidex®) in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 132 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
76th of 366
208 · median 61
Started
2001
with 12 others
Phase 3
60 of 374
3 open now
Registered
24th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 76th largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 60 in phase 3, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women;
  • breast cancer suitable for endocrine therapy;
  • positive hormone receptor status;
  • Human epidermal growth factor receptor 2 () overexpression.

Exclusion criteria

Exclusion Criteria:

  • patients on hormone replacement therapy;
  • previous chemotherapy for disease;
  • uncontrolled cardiac disease and history of cardiac failure.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    trastuzumab + anastrozole

    Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.

    Drug: trastuzumab (Herceptin®) · Drug: anastrazole (Arimidex®)

  • Active comparator
    anastrozole

    1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.

    Drug: anastrazole (Arimidex®)

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm\^2) an increase of 1.0 cm\^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.

    Time frame: 24 Months, End of Study (Up to 5 years)

Secondary outcomes

  1. Percentage of Participants With Clinical Benefit

    Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.

    Time frame: 24 Months, End of Study (Up to 5 years)

  2. Duration of Response at 24 Months

    Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

    Time frame: 24 Months

  3. Time to Response at 24 Months

    Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

    Time frame: 24 Months

  4. Overall Survival at 24 Months

    Overall Survival is defined as the number of days from randomization to death.

    Time frame: 24 Months

  5. Percentage of Participants With Two-Year Survival

    Time frame: 24 Months

  6. Percentage of Participants With Overall Tumor Response at 24 Months

    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

    Time frame: 24 Months

  7. Percentage of Participants With Best Tumor Response at 24 Months

    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

    Time frame: 24 Months

  8. Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline

    Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than \>50% of waking hours; 3=Capable of limited self-care, confined to bed or chair \>50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead. The percentage of participants in the following categories: Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.

    Time frame: Baseline, Final Visit (Up to 24 Months)

  9. Duration of Response at End of Study

    Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

    Time frame: End of Study (Up to 5 years)

  10. Time to Response at End of Study

    Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

    Time frame: End of Study (Up to 5 years)

  11. Percentage of Participants With Overall Tumor Response at End of Study

    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

    Time frame: End of Study (Up to 5 years)

  12. Percentage of Participants With Best Tumor Response at End of Study

    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

    Time frame: End of Study (Up to 5 years)

  13. Number of Participants With Adverse Events

    Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.

    Time frame: Throughout the Study (Up to 5 years)

07

Results

Posted Jun 13, 2013

Participant flow

Main Phase: 24 Months
Participant flow — Main Phase: 24 Months
MilestoneTrastuzumab + AnastrozoleAnastrozole
Started103104
Safety set: received study drug103104
Completed164
Not completed87100
Withdrew: Adverse event60
Withdrew: Death03
Withdrew: Insufficient therapeutic response7591
Withdrew: Violation of selection criteria at entry01
Withdrew: Other protocol violation10
Withdrew: Refused treatment34
Withdrew: Failure to return11
Withdrew: Other10
Extension Phase
Participant flow — Extension Phase
MilestoneTrastuzumab + AnastrozoleAnastrozole
Started1458
Safety set: received study drug1458
Completed117
Not completed351
Withdrew: Adverse event13
Withdrew: Death01
Withdrew: Insufficient therapeutic response144
Withdrew: Refused treatment02
Withdrew: Other11

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm\^2) an increase of 1.0 cm\^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.

Time frame:
24 Months, End of Study (Up to 5 years)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTrastuzumab + AnastrozoleAnastrozole
24 Months4.8 (3.7 to 7)2.4 (2 to 4.6)
End of Study5.8 (4.6 to 8.3)2.9 (2.1 to 4.5)
SecondaryPercentage of Participants With Clinical Benefit

Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.

Time frame:
24 Months, End of Study (Up to 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
24 Months42.727.9
End of Study45.630.8
SecondaryDuration of Response at 24 Months

Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

Time frame:
24 Months
Reported as:
Median · Months
Duration of Response at 24 Months
MonthsTrastuzumab + AnastrozoleAnastrozole
Duration of Response at 24 Months9.5 (3.8 to 50.6)10.0 (5.3 to 33.1)
SecondaryTime to Response at 24 Months

Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

Time frame:
24 Months
Reported as:
Median · Months
Time to Response at 24 Months
MonthsTrastuzumab + AnastrozoleAnastrozole
Time to Response at 24 Months2.0 (1.4 to 12.1)2.0 (1.7 to 4.1)
SecondaryOverall Survival at 24 Months

Overall Survival is defined as the number of days from randomization to death.

Time frame:
24 Months
Reported as:
Median · Months
Overall Survival at 24 Months
MonthsTrastuzumab + AnastrozoleAnastrozole
Overall Survival at 24 Months28.5 (22.8 to 42.4)23.9 (18.2 to 37.4)
SecondaryPercentage of Participants With Two-Year Survival
Time frame:
24 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Two-Year Survival
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Percentage of Participants With Two-Year Survival52.445.2
SecondaryPercentage of Participants With Overall Tumor Response at 24 Months

Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

Time frame:
24 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Tumor Response at 24 Months
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Percentage of Participants With Overall Tumor Response at 24 Months20.36.8
SecondaryPercentage of Participants With Best Tumor Response at 24 Months

Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

Time frame:
24 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Tumor Response at 24 Months
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Complete Response0.00.0
Partial Response20.36.8
Stable Disease37.838.4
Progressive Disease40.549.3
Response not assessed1.45.5
SecondaryPercentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline

Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than \>50% of waking hours; 3=Capable of limited self-care, confined to bed or chair \>50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead. The percentage of participants in the following categories: Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.

Time frame:
Baseline, Final Visit (Up to 24 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Improved10.34.1
No Change67.664.4
Worse22.131.5
SecondaryDuration of Response at End of Study

Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

Time frame:
End of Study (Up to 5 years)
Reported as:
Median · Months
Duration of Response at End of Study
MonthsTrastuzumab + AnastrozoleAnastrozole
Duration of Response at End of Study12.3 (3 to 59.1)8.2 (2.6 to 60.5)
SecondaryTime to Response at End of Study

Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

Time frame:
End of Study (Up to 5 years)
Reported as:
Median · Months
Time to Response at End of Study
MonthsTrastuzumab + AnastrozoleAnastrozole
Time to Response at End of Study2.4 (1.7 to 12.1)2.1 (1.3 to 5.1)
SecondaryPercentage of Participants With Overall Tumor Response at End of Study

Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

Time frame:
End of Study (Up to 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Tumor Response at End of Study
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Percentage of Participants With Overall Tumor Response at End of Study22.38.7
SecondaryPercentage of Participants With Best Tumor Response at End of Study

Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

Time frame:
End of Study (Up to 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Tumor Response at End of Study
Percentage of participantsTrastuzumab + AnastrozoleAnastrozole
Complete Response1.03.8
Partial Response21.44.8
Stable Disease47.640.4
Progressive Disease28.146.2
Response not assessed1.94.8
SecondaryNumber of Participants With Adverse Events

Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.

Time frame:
Throughout the Study (Up to 5 years)
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsTrastuzumab + AnastrozoleAnastrozole
Number of Participants With Adverse Events9068

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab + Anastrozole—25/103 (24.3%)89/103 (86.4%)
Anastrozole—6/104 (5.8%)68/104 (65.4%)
Anastrozole (After Start of Trastuzumab)—8/58 (13.8%)40/58 (69%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventTrastuzumab + AnastrozoleAnastrozoleAnastrozole (After Start of Trastuzumab)
VomitingGastrointestinal disorders3/1030/1040/58
Chest painGeneral disorders3/1030/1040/58
NauseaGastrointestinal disorders2/1030/1040/58
PainGeneral disorders2/1030/1040/58
HypercalcaemiaMetabolism and nutrition disorders2/1030/1040/58
Pathological fractureMusculoskeletal and connective tissue disorders1/1030/1041/58
HypertensionVascular disorders1/1030/1041/58
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1031/1041/58
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1030/1041/58
DyspepsiaGastrointestinal disorders0/1030/1041/58
Most frequent other events
Showing 10 of 31
Most frequent other events
EventTrastuzumab + AnastrozoleAnastrozoleAnastrozole (After Start of Trastuzumab)
FatigueGeneral disorders22/10310/1044/58
VomitingGastrointestinal disorders21/1035/1045/58
DiarrhoeaGastrointestinal disorders20/1038/1048/58
PyrexiaGeneral disorders17/1036/1044/58
NasopharyngitisInfections and infestations17/1032/1042/58
NauseaGastrointestinal disorders15/1035/1045/58
ChillsGeneral disorders15/1030/1043/58
ArthralgiaMusculoskeletal and connective tissue disorders15/1039/1043/58
Back painMusculoskeletal and connective tissue disorders15/1037/1043/58
CoughRespiratory, thoracic and mediastinal disorders15/1036/1044/58

Baseline characteristics

Age Continuous
Age Continuous(years)Trastuzumab + AnastrozoleAnastrozoleTotal
Mean57.4 ± 10.655.5 ± 10.756.5 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab + AnastrozoleAnastrozoleTotal
Female103104207
Male000
08

Study locations

132 sites
  • Phoenix, Arizona 85006, United States
  • Little Rock, Arkansas 72205-7199, United States
  • Los Angeles, California 90048, United States
  • Vallejo, California 94589, United States
  • Gainsville, Florida 32605, United States
  • Miami, Florida 33176, United States
  • Plantation, Florida 33324, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60637, United States
  • Kansas City, Kansas 66160, United States
  • Scarborough, Maine 04074, United States
  • Detroit, Michigan 48202-2689, United States
  • Omaha, Nebraska 68114, United States
  • Hackensack, New Jersey 07601, United States
  • Albuquerque, New Mexico 87131-5636, United States
  • Santa Fe, New Mexico 87505, United States
  • Rochester, New York 14642, United States
  • Cincinnati, Ohio 45267-0562, United States
  • Cleveland, Ohio 44106, United States
  • Hershey, Pennsylvania 17033-0850, United States
  • Box Hill, 3128, Australia
  • Darlinghurst, 2010, Australia
  • Waratah, 2298, Australia
  • Porto Alegre, 90610-000, Brazil
  • Plovdiv, 4000, Bulgaria
  • Sofia, 1527, Bulgaria
  • Stara Zagora, 8000, Bulgaria
  • Calgary, Alberta T2N 4N2, Canada
  • Edmonton, Alberta T6G 1Z2, Canada
  • Victoria, British Columbia V8R 6V5, Canada
  • Winnipeg, Manitoba R3E 0V9, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Quebec City, Quebec G1S 4L8, Canada
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Shanghai, 200025, China
  • Shanghai, 200032, China
  • Wuhan, 430030, China
  • Avignon, 84082, France
  • Nice, 06189, France
  • Frankfurt, 60596, Germany
  • Kiel, 24105, Germany
  • München, 80637, Germany
  • Trier, 54290, Germany
  • Hong Kong, Hong Kong
  • Budapest, H-1122, Hungary
  • Ahmedabad, 380 016, India
  • Bangalore, 560 029, India
  • Chennai, 600 020, India
  • Cuttack, 753 007, India
  • Ludhiana, 141 001, India
  • Mumbai, 400012, India
  • New Delhi, 110 029, India
  • New Delhi, 110 060, India
  • New Delhi, 110085, India
  • Haifa, 31096, Israel
  • Haifa, 34362, Israel
  • Petach Tikva, 49100, Israel
  • Ramat-gan, 52621, Israel
  • Rehovot, 76100, Israel
  • Tel Aviv, 64239, Israel
  • Genova, 16132, Italy
  • Vilnius, 2600, Lithuania
  • Guadalajara, 44340, Mexico
  • Mexico City, 14000, Mexico
  • Amsterdam, 1081 HV, Netherlands
  • Rotterdam, 3075 EA, Netherlands
  • Trondheim, 7006, Norway
  • Bialystok, 15-027, Poland
  • Bydgoszcz, 85-796, Poland
  • Gliwice, 44-101, Poland
  • Krakow, 31-115, Poland
  • Lodz, 94-306, Poland
  • Szczecin, 71-730, Poland
  • Warszawa, 00-909, Poland
  • Warszawa, 02-781, Poland
  • Barnaul, 656049, Russian Federation
  • Izhevsk, 426009, Russian Federation
  • Kazan, 420029, Russian Federation
  • Krasnodar, 350080, Russian Federation
  • Moscow, 107005, Russian Federation
  • Moscow, 115478, Russian Federation
  • Moscow, 117837, Russian Federation
  • Moscow, 121356, Russian Federation
  • Moscow, 125284, Russian Federation
  • St Petersburg, 189646, Russian Federation
  • St Petersburg, 197022, Russian Federation
  • St Petersburg, 197758, Russian Federation
  • UFA, 450054, Russian Federation
  • Floracliffe, 1715, South Africa
  • Pretoria, South Africa
  • Barcelona, 08036, Spain
  • Córdoba, 14004, Spain
  • Girona, 17007, Spain
  • Madrid, 28007, Spain
  • Madrid, 28034, Spain
  • Madrid, 28041, Spain

Showing the first 100 of 132 sites across 26 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2001
First posted
Jan 27, 2003
Start
Jan 2001
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jun 13, 2013
Last update
Jun 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00022672
Lead sponsor
Hoffmann-La Roche
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
Jan 2001
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jun 13, 2013
Last update
Jun 13, 2013

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion